Skip to main content
. Author manuscript; available in PMC: 2011 Nov 15.
Published in final edited form as: Semin Radiat Oncol. 2009 Jan;19(1):63–68. doi: 10.1016/j.semradonc.2008.09.009

Figure 2. Dasatinib re-sensitizes cetuximab-resistant cells to cetuximab therapy.

Figure 2

A: Dasatinib re-sensitizes cetuximab-resistant cells to cetuximab therapy. Cetuximab-resistant cells were treated with DMSO, cetuximab (100nM, CTX), dasatinib (25nM, DSB) or the combination for 72 hours. Growth was measured at 72 hours after drug treatment using the growth proliferation assay as described in the experimental procedures and plotted as a percentage of growth relative to the untreated control cells. Data points are represented as mean ±SEM (n=3). *, P<0.05

B: Dual blockade of SFKs and EGFR have additive effects on Akt and MAPK activity. HC4 cells were plated and treated with the vehicle DMSO (control), 100nM cetuximab, 25nM dasatinib or the combination for 48 hours. Cells were harvested and protein was collected, fractionated by SDS-PAGE and immunoblotted for the indicated proteins. a-tubulin was used as a loading control.